We are monitoring the impact of COVID-19 on MEA Cancer Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 162
Share on
Share on

Middle East & Africa Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, Type, Conjugated Cancer Therapies & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 162
Pages: 145

MEA Cancer Monoclonal Antibodies Market Size (2021 to 2026)

The Cancer Monoclonal Antibodies Market in Middle East & Africa is estimated to be USD 3.34 Billion in 2021 and is expected to reach USD 5.69 Billion by 2026, growing at a CAGR of 11.272% between 2021 to 2026.

Monoclonal antibodies are very effective in treating various cancer diseases and promote the wellbeing of the patient with very few side effects comparatively. This attribute is considered to be a major one driving the demand of the market in the Middle East & Africa. Increasing incidences of cancer diseases across the region are fuelling the growth rate of the market. Also, growing support from the government bodies by introducing various schemes in concern towards common people is accelerating the demand of the cancer monoclonal antibodies market in the Middle East & Africa.

However, the cost for this treatment procedure is a bit expensive where common people cannot afford is quietly hampering the growth rate of the market. People in rural areas are also unaware of the availability of treatment procedures. This is a challenging thing for the market developers in Middle East & Africa. Less availability of skilled doctors is also inhibiting the demand of the cancer monoclonal antibodies market. Rapid changes in economic strategies may also impact negatively on the growth of this market.

Growth opportunities for the market lie in the increasing awareness of the treatment procedures for cancer through campaigns and digital advertisements, especially in undeveloped countries. Growing investments in the development of new technologies in the medical sector by both public and private organizations is greatly influencing the demand for the cancer monoclonal antibodies market in the Middle East & Africa.

This research report on the Middle East and Africa Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:

By Application: 

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkin’s And Non-Hodgkin’s Lymphoma
  • Colorectal
  • Leukaemia
  • Others

By Type: 

  • Murine Antibodies
  • Chimeric & Humanised Antibodies
  • Fully Humanized Antibodies

By Conjugated Cancer Therapies: 

  • Immunoliposome
  • Radioimmunotherapy
  • ADEPT
  • Immunocytokines
  • Others

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regionally, Saudi Arabia is accounted for holding the largest shares of the market by owing to the launch of new techniques in the medical sector. Also, increasing research and development centers in the biotechnology field is leveraging the demand of the market. South Africa and the Rest of the Middle East & Africa are anticipated to have a significant growth rate in the coming years. The growing prevalence of early diagnosis is to bolster the growth rate if the cancer monoclonal antibodies market.

Noteworthy Companies dominating the MEA Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis & Spectrum Pharmaceuticals.

  1. Introduction

                1.1 Market Definition                                                                    

                1.2 Study Deliverables                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                          

                1.4 General Study Assumptions                                                                

  1. Research Methodology

                2.1 Introduction                                                                               

                2.2 Research Phases                                                                      

                                2.2.1 Secondary Research                                                           

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design                                                                         

                2.4 Study Timeline                                                                          

  1. Overview

                3.1 Executive Summary                                                                

                3.2 Key Inferences                                                                         

                3.3 New Developments                                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                                          

                4.2 Market Restraints                                                                    

                4.3 Key Challenges                                                                         

                4.4 Current Opportunities in the Market                                                                              

  1. Market Segmentation

                5.1 By Application                                                                           

                                5.1.1 Liver                                                           

                                5.1.2 Breast                                                       

                                5.1.3 Brain                                                          

                                5.1.4 Blood                                                         

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma                                                    

                                5.1.6 Colorectal                                                

                                5.1.7 Leukaemia                                                              

                                5.1.8 Others                                                      

                5.2 By Type                                                                        

                                5.2.1 Murine Antibodies                                                              

                                5.2.2 Chimeric and Humanised Antibodies                                                           

                                5.2.3 Fully Humanized Antibodies                                                            

                5.3 Conjugate Cancer Therapies                                                                               

                                5.3.1 Immunoliposome                                                

                                5.3.2 Radioimmunotherapy                                                        

                                5.3.3 ADEPT                                                       

                                5.3.4 Immunocytokines                                                

                                5.3.5 Others                                                      

  1. Geographical Analysis

                6.1 Introduction                                                                               

                6.2 UAE                                                                               

                6.3Saudi Arabia                                                                

                6.4 Israel                                                                             

                6.5 Others                                                                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                                                         

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social                                                         

                                7.1.4 Technological                                                         

                                7.1.5 Legal                                                          

                                7.1.6 Environmental                                                       

                7.2 Porter’s Five analysis                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                        

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                     

  1. Market Leaders' Analysis

                8.1 Roche                                                           

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Strategic Evaluation and Operations                                                            

                                8.1.4 Financial analysis                                                  

                                8.1.5 Legal issues                                                             

                                8.1.6 Recent Developments                                                       

                                8.1.7 SWOT analysis                                                       

                                8.1.8 Analyst View                                                          

                8.2 Amgen                                                         

                8.3 Genmab                                                      

                8.4 Glaxosmithkline                                                       

                8.5 Bristol Meyer Squibb                                                              

                8.6 Eli Lilly                                                           

                8.7 Immunogen                                                               

                8.8 Novartis                                                       

                8.9 Seattle Genetics                                                       

                8.10 Spectrum Pharmaceuticals                                                

  1. Competitive Landscape

                9.1 Market share analysis                                                                            

                9.2 Merger and Acquisition Analysis                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                         

                9.4 New Product Launches                                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                                     

                10.2 Investment Opportunities                                                                 

     Appendix                                                                                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Cancer Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  2. Middle East & Africa Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  3. Middle East & Africa Liver Market, By Region, From 2021 to 2026 (USD Million)
  4. Middle East & Africa Breast Market, By Region, From 2021 to 2026 (USD Million)
  5. Middle East & Africa Brain Market, By Region, From 2021 to 2026 (USD Million)
  6. Middle East & Africa Blood Market, By Region, From 2021 to 2026 (USD Million)
  7. Middle East & Africa Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  8. Middle East & Africa Colorectal Market, By Region, From 2021 to 2026 (USD Million)
  9. Middle East & Africa Leukaemia Market, By Region, From 2021 to 2026 (USD Million)
  10. Middle East & Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  11. Middle East & Africa Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  12. Middle East & Africa Murine Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  13. Middle East & Africa Chimeric and Humanised Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  14. Middle East & Africa Fully Humanized Antibodies Market, By Region, From 2021 to 2026 (USD Million)
  15. Middle East & Africa Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  16. Middle East & Africa Immunoliposome Market, By Region, From 2021 to 2026 (USD Million)
  17. Middle East & Africa Radioimmunotherapy Market, By Region, From 2021 to 2026 (USD Million)
  18. Middle East & Africa ADEPT Market, By Region, From 2021 to 2026 (USD Million)
  19. Middle East & Africa Immunocytokines Market, By Region, From 2021 to 2026 (USD Million)
  20. Middle East & Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  21. UAE Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  22. UAE Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  23. UAE Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  24. Saudi Arabia Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  25. Saudi Arabia Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  26. Saudi Arabia Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)
  27. Israel Cancer Monoclonal Antibodies Market, By Application, From 2021 to 2026 (USD Million)
  28. Israel Cancer Monoclonal Antibodies Market, By Type, From 2021 to 2026 (USD Million)
  29. Israel Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample